NexEos Bio Announces Positive Results from Clinical Study Evaluating NTX-1024 in Patients with Vernal Keratoconjunctivitis

​

MALVERN, PA January 8, 2026 – NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, announces positive results from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with vernal keratoconjunctivitis (VKC).

​

The study was conducted in Mexico and enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period. Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.  

This marks the first clinical study to evaluate NTX-1024 in VKC, a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated. These results reinforce the therapeutic potential of NTX-1024 in VKC and have prompted NexEos to pursue further clinical development.

​​

 “VKC is a debilitating condition that severely impacts patients’ daily lives. The improvements observed with NTX-1024 offer promising new hope in improving symptoms and restoring ocular health in these patients,” commented Dr. Ken Mandell, strategic advisor to NexEos and chair of the VKC study.

​

“Our long-standing focus on eosinophil-mediated inflammation led us to explore ophthalmology, where eosinophil-driven diseases like VKC present a clear unmet need,” said Dr. Gerald Gleich, CSO at NexEos. “This study demonstrates that targeting cationic granule proteins may offer a novel therapeutic approach, and we are proud to partner with dedicated investigators to bring forward new treatment options for patients living with VKC, a rare and serious condition with limited safe and effective therapies available today.”

About NTX-1024

​

NTX-1024 is an investigational topical ophthalmic solution designed to target and inhibit cationic granule proteins in eosinophil-driven ocular disease. It is being developed as a potential first-in class therapy for conditions such as VKC, with future expansion into broader forms of allergic conjunctivitis.

About NexEos Bio

​

NexEos Bio (www.nexeosbio.com) is a privately held medical diagnostics and therapeutics company based in Malvern, Pennsylvania, dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering with eosinophil-related diseases.

 

For more Information, please send inquiries to:  Info@nexeosdx.com